[HTML][HTML] Targeting epigenetic regulators to overcome drug resistance in cancers
N Wang, T Ma, B Yu - Signal transduction and targeted therapy, 2023 - nature.com
Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic
regulation is a heritable change in gene expressions independent of nucleotide sequence …
regulation is a heritable change in gene expressions independent of nucleotide sequence …
[HTML][HTML] Polyphenols as potent epigenetics agents for cancer
Human diseases such as cancer can be caused by aberrant epigenetic regulation.
Polyphenols play a major role in mammalian epigenome regulation through mechanisms …
Polyphenols play a major role in mammalian epigenome regulation through mechanisms …
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications
NSCLC is the leading cause of cancer mortality and represents a major challenge in cancer
therapy. Intrinsic and acquired anticancer drug resistance are promoted by hypoxia and HIF …
therapy. Intrinsic and acquired anticancer drug resistance are promoted by hypoxia and HIF …
Functional correlation of genome‐wide DNA methylation profiles in genetic neurodevelopmental disorders
An expanding range of genetic syndromes are characterized by genome‐wide disruptions in
DNA methylation profiles referred to as episignatures. Episignatures are distinct, highly …
DNA methylation profiles referred to as episignatures. Episignatures are distinct, highly …
[PDF][PDF] Novel diagnostic DNA methylation episignatures expand and refine the epigenetic landscapes of Mendelian disorders
MA Levy, H McConkey, J Kerkhof… - Human Genetics and …, 2022 - cell.com
Overlapping clinical phenotypes and an expanding breadth and complexity of genomic
associations are a growing challenge in the diagnosis and clinical management of …
associations are a growing challenge in the diagnosis and clinical management of …
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
S Chen, Y Zhao, S Liu, J Zhang, YG Assaraf… - Drug Resistance …, 2022 - Elsevier
Despite the rapid advancement in the introduction of new drugs for cancer therapy, the
frequent emergence of drug resistance leads to disease progression or tumor recurrence …
frequent emergence of drug resistance leads to disease progression or tumor recurrence …
[HTML][HTML] A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer
therapy. However,< 50% of patients have an objective response, and nearly all patients …
therapy. However,< 50% of patients have an objective response, and nearly all patients …
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer
Prostate cancer (PC) is the most prevalent male urogenital cancer worldwide. PC patients
presenting an advanced or metastatic cancer succumb to the disease, even after therapeutic …
presenting an advanced or metastatic cancer succumb to the disease, even after therapeutic …
[HTML][HTML] The role of histone protein acetylation in regulating endothelial function
Z Fang, X Wang, X Sun, W Hu, QR Miao - Frontiers in Cell and …, 2021 - frontiersin.org
Endothelial cell (EC), consisting of the innermost cellular layer of all types of vessels, is not
only a barrier composer but also performing multiple functions in physiological processes. It …
only a barrier composer but also performing multiple functions in physiological processes. It …
[HTML][HTML] Protein acetylation and related potential therapeutic strategies in kidney disease
X Li, J Yu, Y Dong, X Shen, R Hou, M Xie, J Wei… - Pharmacological …, 2023 - Elsevier
Kidney disease can be caused by various internal and external factors that have led to a
continual increase in global deaths. Current treatment methods can alleviate but do not …
continual increase in global deaths. Current treatment methods can alleviate but do not …